RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsMay 29, 2024 - Amgen Wins FDA Approval for First Biosimilar to AstraZeneca’s Soliris Soliris was first approved by the FDA in 2007 for PNH. At the time, it was still owned by rare disease player Alexion Pharmaceuticals, which AstraZeneca acquired in 2020 for $39 billion.
The investment has been paying off for AstraZeneca with Soliris consistently serving as one of its best-selling products. In 2023, Soliris was the pharma’s top rare disease asset bringing in $3.1 billion despite suffering a 14% decline in sales. Overall, Soliris was outperformed only by the cancer drugs Tagrisso (osimertinib) and Imfinzi (durvalumab), and the heart failure therapy Farxiga (dapagliflozin).
https://www.biospace.com/article/amgen-wins-fda-approval-for-first-interchangeable-biosimilar-to-astrazeneca-s-soliris/